Merck to Acquire Rapid Micro Biosystems to Boost Pharma Quality Control

Merck KGaA, Darmstadt, Germany, has signed a definitive agreement to acquire Rapid Micro Biosystems, a US-based company specialising in automated microbial testing for pharmaceutical manufacturing. The proposed acquisition is expected to strengthen Merck’s Life Science business and expand its range of automated quality-control solutions for the pharmaceutical industry.

Under the agreement, Merck will acquire Rapid Micro Biosystems for $0.75 per share in cash. The transaction is expected to close in December 2026, subject to customary closing conditions, including the required shareholder tender.

Rapid Micro Biosystems develops instruments, software, consumables and services that help pharmaceutical manufacturers automate microbial quality-control testing. Its main product, the Growth Direct platform, is designed to make microbial testing faster and reduce the need for manual laboratory work.

The Growth Direct system automates several testing steps, including sample incubation, imaging and colony counting. It is used by pharmaceutical manufacturers for environmental monitoring, water testing and bioburden testing.

The technology can detect microbial growth during the incubation process, helping laboratories receive results faster than traditional manual testing methods. It also digitises sample tracking and test results, reducing manual data entry and supporting better data accuracy.

Merck plans to integrate the Growth Direct platform into its existing pharmaceutical quality-control portfolio. The move is expected to strengthen its capabilities in environmental monitoring, in-process testing and product release testing.

The acquisition also supports Merck’s strategy to develop integrated workflow solutions for pharmaceutical manufacturing. As the production of biologics and advanced therapies, including cell and gene therapies, becomes more complex, manufacturers are increasingly looking for faster and more reliable quality-control methods.

Paolo Carli, Head of Advanced Solutions for Merck’s Life Science business, said the acquisition would strengthen the company’s ability to provide faster testing results, more efficient quality-control processes and improved data integrity for pharmaceutical manufacturers.

Robert Spignesi, President and CEO of Rapid Micro Biosystems, said joining Merck would create opportunities to combine the company’s automation expertise with a broader range of pharmaceutical quality-control solutions.

The proposed acquisition builds on an existing global distribution and collaboration agreement between the two companies announced in February 2025.

The deal is expected to expand Merck’s presence in automated pharmaceutical quality control while helping manufacturers improve laboratory efficiency, reduce manual processes and support the growing demands of modern drug production.

Comments (0)
Add Comment